Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xizang Haisco Pharma Invests $10 Million in Endospan of Israel

publication date: Oct 22, 2015
Xizang Haisco Pharmaceutical Group, located in China's Tibet region, invested $10 million in Israeli medical device maker Endospan, a company that makes aortic stents. With the investment, Haisco obtained China rights to Endospan's two devices: the Nexus™, which repairs damage to the aortic arch, and the Horizon™, which repairs abdominal aortic aneurysms. Endoscan, which raised $25 million in the funding, says its devices are less invasive than the competition. More details....

Stock Symbol: (SHZ: 002653)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital